Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated...
adminph
Laura Vergani
Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined...
NICE recommendation for new Alexion PNH treatment
danicopan shown to improve haemoglobin levels and reduce anaemia Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health...
Repurposing mifepristone: new hope for anti-aging treatments
New research from biologists at the USC Dornsife College of Letters, Arts and Sciences reveals that mifepristone, a drug best...
Darzalex subcutaneous regimen approved by European Commission
New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of...
Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug
CAL101 shows promising results and is set to enter phase 2 development Calluna Pharma AS has announced the successful completion...
U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus...
Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year Valneva Scotland has partnered with Team Jak,...
Expanding access to weight-loss drugs could save thousands of lives a year
Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States,...
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for...
Learna and University of Wolverhampton launch flexible healthcare courses
The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton...
World-first clinical trial for treating spinal cord injury using olfactory cell nerve bridges
Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised...
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study...
New £4.5m initiative launched to address UK medicines manufacturing skills shortage
The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address...
Vivan renews five-year lease at UK biotech hub White City Place
The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a...
Drug discovery within the patient
The idea of using microorganisms as a source of new active ingredients is not new. Numerous drugs have already been...
HBC Immunology shares promising results for prostate cancer co-therapy
There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an...
Richard Hopkins
NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its...
Specific type of DNA could be a target of future cancer therapies
Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher...
